Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Clinical Potential
100%
Once-daily Regimen
100%
Lixisenatide
100%
Glucagon-like
45%
A1 Receptor
36%
Postprandial Glucose
27%
Receptor Agonist
27%
Fasting Plasma Glucose
27%
Liraglutide
18%
Exenatide
18%
Basal Insulin
18%
GetGoal
18%
Cardiovascular Events
9%
Cardiovascular Mortality
9%
Adverse Events
9%
Placebo
9%
Acute Coronary Syndrome
9%
Glycemia
9%
Insulin
9%
Hemoglobin A1c (HbA1c)
9%
Type 2 Diabetic Patients
9%
Clinical Development
9%
Monotherapy
9%
Glucagon Secretion
9%
Insulin Secretion
9%
European Medicines Agency
9%
Physiological Effects
9%
Glycated Hemoglobin A1c
9%
Gastrointestinal Motility
9%
Satiety
9%
General Trends
9%
Head-to-head Trials
9%
Postprandial Glucose Excursion
9%
Insulin Glargine
9%
Secretion Inhibition
9%
Oral Antidiabetic Agents
9%
Once-daily Administration
9%
Lantus
9%
Combination Products
9%
Place in Therapy
9%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Lixisenatide
100%
Glucagon-Like Peptide-1 Agonist
25%
Hemoglobin A1c
16%
Liraglutide
16%
Exenatide
16%
Insulin Glargine
16%
Cardiovascular System
8%
Placebo
8%
Adverse Event
8%
Acute Coronary Syndrome
8%
Oral Antidiabetic Agent
8%
Patient with Type 2 Diabetes
8%
Medicine
8%
Clinical Study
8%
Insulin Release
8%
Glucagon Release
8%
Glycated Hemoglobin
8%
Monotherapy
8%
Glucagon Like Peptide 1
8%
Glucagon Like Peptide 1 Receptor
8%
Gastrointestinal Motility
8%
Satiety
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Lixisenatide
100%
Glucagon Like Peptide 1 Receptor Agonist
25%
Hemoglobin A1c
16%
Liraglutide
16%
Exendin 4
16%
Insulin Glargine
16%
Adverse Event
8%
Placebo
8%
Acute Coronary Syndrome
8%
Oral Antidiabetic Agent
8%
Monotherapy
8%
Clinical Study
8%
Glucagon
8%
Glycosylated Hemoglobin
8%
Glucagon-Like Peptide-1
8%
Glucagon-Like Peptide 1 Receptor
8%